Subsequently, a third-generation EGFR inhibitor named osimertinib was developed, which works by sensitizing and antagonizing EGFR T790M-containing mutant NSCLC cells; it has demonstrated increased overall survival compared to first-generation inhibitors [19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.